Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.

The factor VIII C2 domain is a highly immunogenic domain, whereby inhibitory antibodies develop following factor VIII replacement therapy for congenital hemophilia A patients. Inhibitory antibodies also arise spontaneously in cases of acquired hemophilia A. The structural basis for molecular recognition by 2 classes of anti-C2 inhibitory antibodies that bind to factor VIII simultaneously was investigated by x-ray crystallography. The C2 domain/3E6 FAB/G99 FAB ternary complex illustrates that each antibody recognizes epitopes on opposing faces of the factor VIII C2 domain. The 3E6 epitope forms direct contacts to the C2 domain at 2 loops consisting of Glu2181-Ala2188 and Thr2202-Arg2215, whereas the G99 epitope centers on Lys2227 and also makes direct contacts with loops Gln2222-Trp2229, Leu2261-Ser2263, His2269-Val2282, and Arg2307-Gln2311. Each binding interface is highly electrostatic, with positive charge present on both C2 epitopes and complementary negative charge on each antibody. A new model of membrane association is also presented, where the 3E6 epitope faces the negatively charged membrane surface and Arg2320 is poised at the center of the binding interface. These results illustrate the potential complexities of the polyclonal anti-factor VIII immune response and further define the "classical" and "nonclassical" types of antibody inhibitors against the factor VIII C2 domain.

[1]  E. Saenko,et al.  A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor (*) , 1995, The Journal of Biological Chemistry.

[2]  P. Lenting,et al.  The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.

[3]  B. Stoddard,et al.  Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. , 2001, Blood.

[4]  B. Atanasov,et al.  A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF‐binding site distant from its epitope , 2010, Journal of thrombosis and haemostasis : JTH.

[5]  H. Hemker,et al.  The role of phospholipid and factor VIIIa in the activation of bovine factor X. , 1981, The Journal of biological chemistry.

[6]  P. Lollar,et al.  Subunit structure of thrombin-activated porcine factor VIII. , 1989, Biochemistry.

[7]  Letter: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.

[8]  M. Shima,et al.  Common inhibitory effects of human anti‐C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor , 1995, British journal of haematology.

[9]  Nathan A. Baker,et al.  Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M F Hoylaerts,et al.  Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. , 1998, Blood.

[11]  T. Koide,et al.  Factor VIII C2 Domain Contains the Thrombin-binding Site Responsible for Thrombin-catalyzed Cleavage at Arg1689 * , 2000, The Journal of Biological Chemistry.

[12]  K. Fujikawa,et al.  Structure of the C2 domain of human factor VIII at 1.5 Å resolution , 1999, Nature.

[13]  Shapiro,et al.  A Multicenter Study of Recombinant Factor VI11 (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A , 2000 .

[14]  S. Meeks,et al.  Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. , 2007, Blood.

[15]  G. Lippi,et al.  Acquired factor VIII inhibitors. , 2008, Blood.

[16]  L. Hoyer,et al.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. , 1989, The Journal of clinical investigation.

[17]  M. Shima,et al.  A role for the C2 domain of factor VIII in binding to von Willebrand factor. , 1994, The Journal of biological chemistry.

[18]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[19]  B. Furie,et al.  Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. , 2008, Structure.

[20]  M. Shima,et al.  A Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Factor VIII Binding to von Willebrand Factor and to Phosphatidylserine , 1993, Thrombosis and Haemostasis.

[21]  J. Freyssinet,et al.  Human factor VIII procoagulant activity and phospholipid interaction. , 1981, Biochimica et biophysica acta.

[22]  E. Saenko,et al.  The Acidic Region of the Factor VIII Light Chain and the C2 Domain Together Form the High Affinity Binding Site for von Willebrand Factor* , 1997, The Journal of Biological Chemistry.

[23]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[24]  G. E. Gilbert,et al.  A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function. , 2011, Blood.

[25]  B. Stoddard,et al.  Disruption of protein-membrane binding and identification of small-molecule inhibitors of coagulation factor VIII. , 2004, Chemistry & biology.

[26]  L. Hoyer,et al.  Immunochemical characterization of factor VIII inhibitors. , 1984, Progress in clinical and biological research.

[27]  J. Oldenburg,et al.  Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. , 2002, Seminars in thrombosis and hemostasis.

[28]  S. Kaveri,et al.  Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. , 2012, Biochemistry.

[29]  A. Thompson,et al.  The factor VIII C1 domain contributes to platelet binding. , 2008, Blood.

[30]  J. Lusher,et al.  The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[32]  G. Knutson,et al.  Molecular cloning of a cDNA encoding human antihaemophilic factor , 1984, Nature.

[33]  L. Hoyer,et al.  Inactivation of factor VIII coagulant activity by two different types of human antibodies. , 1982, Blood.

[34]  E. Chen,et al.  Characterization of the human factor VIII gene , 1984, Nature.

[35]  T. Suzuki,et al.  Role of factor VIII C2 domain in factor VIII binding to factor Xa. , 1999, The Journal of biological chemistry.

[36]  J. Saint-Remy,et al.  Factor VIII Inhibitors , 1997, Thrombosis and Haemostasis.

[37]  K. Titani,et al.  A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. , 1987, The Journal of biological chemistry.

[38]  J. Brown,et al.  Interaction Of Factor VIII/Von Willebrand Factor With Phospholipid Vesicles , 1981, Thrombosis and Haemostasis.

[39]  Scharrer,et al.  Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  B. Stoddard,et al.  Surface-exposed Hemophilic Mutations across the Factor VIII C2 Domain Have Variable Effects on Stability and Binding Activities* , 2004, Journal of Biological Chemistry.

[41]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[42]  Gerry A. F. Nicolaes,et al.  Trp2313-His2315 of Factor VIII C2 Domain Is Involved in Membrane Binding , 2010, The Journal of Biological Chemistry.

[43]  W. Kane,et al.  Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. , 1988, Blood.

[44]  D. Okita,et al.  Human CD4+ T‐cell epitope repertoire on the C2 domain of coagulation factor VIII , 2003, Journal of thrombosis and haemostasis : JTH.

[45]  P. Fay,et al.  Factor VIII Lacking the C2 Domain Retains Cofactor Activity in Vitro* , 2010, The Journal of Biological Chemistry.

[46]  E. Gordon,et al.  A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. , 1994, Blood.

[47]  R. Kaufman,et al.  Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-binding and von Willebrand Factor-binding Motifs* , 2002, The Journal of Biological Chemistry.

[48]  Y. Sakata,et al.  The Factor VIIIa C2 Domain (Residues 2228–2240) Interacts with the Factor IXa Gla Domain in the Factor Xase Complex* , 2009, Journal of Biological Chemistry.

[49]  S. Meeks,et al.  Characterization and Solution Structure of the Factor VIII C2 Domain in a Ternary Complex with Classical and Non-classical Inhibitor Antibodies* , 2013, The Journal of Biological Chemistry.

[50]  K. Nogami,et al.  Anticoagulant effects of a synthetic peptide containing residues Thr‐2253–Gln‐2270 within factor VIII C2 domain that selectively inhibits factor Xa‐catalysed factor VIII activation , 2002, British journal of haematology.

[51]  I. Scharrer,et al.  The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. , 1997, Blood.

[52]  S. Meeks,et al.  Non‐classical anti‐factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model , 2008, Journal of thrombosis and haemostasis : JTH.

[53]  K. Fischer,et al.  Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[54]  B. Shen,et al.  The tertiary structure and domain organization of coagulation factor VIII. , 2008, Blood.

[55]  S. Meeks,et al.  Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. , 2008, Blood.

[56]  P. Lollar,et al.  Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[57]  K. Nogami,et al.  Interactions between residues 2228–2240 within factor VIIIa C2 domain and factor IXa Gla domain contribute to propagation of clot formation , 2011, Thrombosis and Haemostasis.

[58]  V. Novakovic,et al.  Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity. , 2012, Blood.

[59]  W. Hoots.  The future of plasma‐derived clotting factor concentrates , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[60]  K. Fischer,et al.  Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. , 2001 .

[61]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[62]  G. E. Gilbert,et al.  Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. , 1995, Blood.

[63]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.